Tag - QURE

Developments

uniQure doses first patients in Phase 1/2 Huntington’s disease gene therapy trial

uniQure (NASDAQ:QURE) dosed the first two patients in its Phase 1/2 trial evaluating AMT-130 for the treatment of Huntington’s disease (HD). HD is an inherited neurodegenerative disorder where production and aggregation...

June 19, 2020

Developments

uniQure reports new Phase 2b data for hemophilia B gene therapy candidate

uniQure (NASDAQ:QURE) reported new data from its Phase 2b trial of hemophilia B candidate, AMT-061, which demonstrated sustained activity six months after administration in three patients. AMT-061 is a therapy that...

May 10, 2019

Developments

uniQure gets FDA fast track designation for Huntington’s disease gene therapy

uniQure (NASDAQ:QURE) received FDA fast track designation for AMT-130, a gene therapy candidate for the treatment of Huntington’s disease (HD). HD is an inherited neurodegenerative disorder where production and...

April 9, 2019

Tag - QURE

uniQure doses first patients in Phase 1/2 Huntington’s disease gene therapy trial

uniQure reports new Phase 2b data for hemophilia B gene therapy candidate

uniQure gets FDA fast track designation for Huntington’s disease gene therapy

General

More